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Acute and chronic hemodynamic and clinical responses 
to milrinone, a new oral inotrope-vasodilator agent, were 
evaluated prospectively in 37 patients witlI severe 
congestive heart failure. The majority of patients (0 = 
31) had not responded to prior vasodilator therapy, with 
a substantial number (n = 8) requiring intravenous ino-
tropic support at the time of initial study. All patients 
showed acute hemodynamic improvement with oral mil-
rinone, and an optimal maintenance dose was chosen 
for each patient during dose-ranging studies (average 
dose 48 mg/day). Milrinone was discontinued before fol-
low-up hemodynamic study in 12 patients (because of 
worsening congestive heart failure in 6 patients, sudden 
death in 3 patients, arrhythmia in 1 patient and refusal 
by 2 patients). 
Hemodynamic effects of milrinone both acutely and 
after chronic therapy (average 37 days) were compared 
in the remaining 25 patients. Acutely, mean cardiac in-
dex increased from 1.9 ± 0.5 to 2.5 ± 0.5 liters/min 
The concomitant increase in contractile state and decrease 
in resistance to left ventricular ejection combine two im-
portant physiologic principles to enhance cardiac perform-
ance in patients with heart failure (1,2). Milrinone, a bi-
pyridine derivative, is one of a number of pharmacologic 
agents that appear to possess both positive inotropic and 
vasodilating properties (3-10). Milrinone, given intrave-
nously and orally, produces marked acute beneficial hemo-
dynamic effects, even in patients with severe refractory heart 
failure (6,10). However, there is a paucity of information 
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per m2 (p < 0.(01), and mean pulmonary capillary wedge 
pressure decreased from 28 ± 9 to 18 ± 8 mm Hg 
(p < 0.001). When oral milrinone was readministered 
after chronic therapy , m~an cardiac index increased from 
1.9 ± 0.5 to 2.5 ± 1.7 liters/min per m2 (p < 0.001), 
and pulmonary capillary wedge pr~ssure decreased from 
27 ± 8 to 20 ± 8 mm Hg (p < 0.001) at 1 hour. 
New York Heart Association functional class im-
proved in 18 of the 25 P!ltients treated over a long-term 
period (mean 5.5 ± 2.3 months). No major adverse side 
effects were observed with chronic therapy; however, 23 
patients developed fluid retenUon requiring increased 
doses of diuretic drugs. The cumulative survival rate at 
6 months for the entire group was 34%. Hence, milri-
none appears to produce sustained hemodynamic and 
clinical improvement in many patients with severe re-
fractory chronic heart failure, but overall mortality re-
mains high. 
(J Am Coli CardioI1985;6:453-9) 
regarding its hemodynamic and clinical effects during chronic 
therapy. 
Methods 
Study patients (Table 1). Thirty-seven patients with 
severe congestive heart failure were enrolled in the study. 
There were 27 men and 10 women, with an aven~ge age of 
60 years (range 26 to 77). The cause of congestive heart 
failure was ischemic heart disease in 16 patients, idiopathic 
dilated cardiomyopathy in 20 patients and persistent heart 
failure after mitral valve replacement in 1 patient. Twenty" 
four patients were in New York Heart Association functional 
class IV and 13 were in class III at the time of initial 
hemodynamic study. All but one of the patients were re-
ceiving digoxin and all patients were on diuretic therapy. 
Thirty-one of the 37 patients were symptomatic despite 
vasodilator therapy before study (20 received angiotensin-
converting enzyme inhibitors and 11 received other vaso-
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Table 1. Clinical Characteristics of 37 Patients With Severe 
Congestive Heart Failure Treated With Milrinone 
Age (yr) 
Average 
Range 
Sex 
Male 
Female 
Cause of heart failure 
Ischemic heart disease 
Idiopathic cardiomyopathy 
Valvular heart disease 
Duration of heart failure 
Average 
Range 
New York Heart Association class 
III 
IV 
Medications before study 
Qigoxin 
Diuretic drugs 
Vasodilators 
Captopril 
Other 
Intravenous inotrope 
Antiarrhythmic lIgents 
No. of 
Patients 
60 
26 to 77 
27 
10 
16 
20 
44 months 
3 months to 12 years 
13 
24 
36 
37 
31 
20 
11 
8 
20 
dilator agi!nts). Eight patients required intravenous inotropic 
support with either dopamine or dobutamine immediately 
before milrinone therapy was started. Patients continued 
taking digoxin and diuretic drugs, but all vasodilator agents 
were discontinued 24 hours before study. Informed consent 
was obtained from all patients .. 
Hemodynamic measurements. These were made with 
a 7F triple lumen balloon flotation catheter placed into the 
pulmonary artery to determine right atrial, pulmonary artery 
and pulmonary capillary wedge pressures. Cardiac output 
was determined by the thermodilution technique using the 
same catheter (11). Derived hemodynamic values were cal-
culated as follows: cardiac index (CI [liters/min per m2]) = 
CO/BSA, where CO = cardiac output and BSA = body 
surface area (m2). Stroke volume index (SVI [mllm2]) = 
CIIHR, where ijR = heart rate (beats/min). Stroke work 
index (SWI [g-rnIm2]) = (MSP - PCW) x SVI x 0.0136, 
where MSP = mean systolic pressure and PCW = mean 
pulmonary capillary wedge pressure. Systemic vascular re-
sistance (SVR [dynes·s·cm- 5]) = (MAP - RAP)/CO x 
80, where MAP = mean arterial pressure and RAP = mean 
right atrial pressure. Pulmonary vascular resistance (PVR 
[dynes·s·cm- 5]) = (PAP - PCW)/CO x 80, where 
PAP = mean pulmonary artery pressure. 
Milrinone d()sage. After placement of the triple lumen 
catheter, two sets of baseline pressure and cardiac output 
values were obtained. Milrinone was then administered or-
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ally, and hemodynamic measurements were taken at 15, 30, 
45, 60, 90, 120, 240 and 360 minutes after the dose. The 
first 21 patients enrolled were studied using an ascending 
dose-response protocol beginning at 2.5 mg and increasing 
to 5.0, 7.5 and 10 mg, with each higher dose being given 
only after hemodynamic variables returned to baseline after 
each previous dose. The subsequent 16 patients enrolled 
received ascending doses beginning at 7.5 mg and increasing 
to 10, 12.5 and 15 mg. On the basis of initial hemodynamic 
response, an optimal dose for chronic therapy was chosen 
for each patient (average dose 48 mg/day), and 25 patients 
who continued receiving milrinone returned after an average 
of 37 days (range 19 to 89) for repeat hemodynamic study. 
Repeat hemodynamic study. The repeat study utilized 
a protocol similar to that of the initial study, but only a 
single dose (the maintenance dose) was given. The control 
hemodynamic measurements during the second hemody-
namic study were taken 6 hours after the last milrinone dose. 
After administration of the maintenance dose, the hemo-
dynamic measurements were repeated at th~ same time in-
tervals as during the initial hemodynamic study. During 
maintenance therapy, each patient was examined once a 
week to assess changes in symptoms and physical findings. 
Routine laboratory tests were also performed to assess changes 
in renal, hepatic and hematologic functions. 
Statistical analysis. Repeated measures analysis of var-
iance and time by time paired t tests were used to assess 
the hemodynamic effects of each dose for each time interval. 
Peak hemodynamic effects were analyzed for the total group 
of 37 patients studied acutely. Peak effect was defined as 
the time of maximal increase in cardiac output for the dose 
producing the maximal effect after which there was no fur-
ther increase greater than 1 standard deviation of the mean 
as derived py analysis of variance. In the 25 patients who 
were able to continue taking milrinone until the follow-up 
hemodynamic study, acute and chronic hemodynamic ef-
fects for each time interval were analyzed for the dose re-
ceived as an outpatient. The cumulative survival rate was 
determined using a Cox regression analysis and expressed 
by the Kaplan-Meier curve. 
Results 
Hemodynamic Effects 
Acute effects. The peak hemodynamic effects of oral 
milrinone in all 37 patients during the initial evaluation are 
summarized in Table 2. The peak effect was defined in 
relation to the maximal increase in cardiac output after the 
maximal dose an individual patient received. The maximal 
increase in cardiac output occurred at 60 minutes, and the 
changes in systemic hemodynamics at 60 minutes were com-
pared with the baseline values. The acute hemodynamic 
response was characterized by a significant increase in car-
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Table 2. Peak Hemodynamic Effects of Oral Milrinone in 37 
Patients With Severe Congestive Heart Failure 
Baseline Peak Effect p Value 
Heart rate 88 ± 18 95 ± 16 0.0001 
(beats/min) 
MAP 80 ± II 69 ± II 0.0001 
(mm Hg) 
RAP 13 ± 8 7 ± 5 0.0001 
(mm Hg) 
PCW 28 ± 9 18 ± 8 0.0001 
(mm Hg) 
SVR 1.694 ± 485 1.139 ± 287 0.0001 
(dynes's'cm - 5) 
CI 1.9 ± .5 2.4 ± .5 0.0001 
(liters/min per m2) 
SWI 15.6 ± 8.0 22.4 ± 9.6 0.0001 
(g-mlm2) 
SVI 21.8 ± 6.6 31.4 ± 9.5 0.0001 
Values are mean ± standard deviation. CI = cardiac index; MAP = 
mean arterial pressure; PCW = pulmonary capillary wedge pressure; 
RAP = right atrial pressure; SVI = stroke volume index; SVR = systemic 
vascular resistance; SWI = stroke work index. 
diac index ( + 26%), stroke volume index ( + 44%) and stroke 
work index ( + 43%), along with a significant reduction in 
pulmonary capillary wedge pressure (- 36%), right atrial 
pressure ( - 46%) and systemic vascular resistance ( - 33%). 
There was a modest but statistically significant decrease in 
mean arterial pressure and increase in heart rate. 
Hemodynamic response after maintenance therapy. 
The hemodynamic effects of milrinone were reevaluated in 
25 patients after an average of 37 days (range 19 to 89) of 
chronic therapy. In 12 patients, a second hemodynamic 
evaluation could not be performed. Six of the 12 required 
treatment with intravenous dobutamine and dopamine be-
cause of worsening heart failure after initial improvement; 
their hemodynamic status was not determined before the 
intravenous therapy. Three patients died suddenly before 
they could be readmitted for the second hemodynamic eval-
uation. One patient developed ventricular tachycardia and 
milrinone was discontinued. Two patients refused to undergo 
a second right heart catheterization. 
The hemodynamic responses to acute administration of 
milrinone before and after chronic therapy in the remaining 
25 patients were qualitatively similar (Table 3). The hemo-
dynamic values at baseline during initial and late study were 
virtually identical. Cardiac index increased significantly by 
45 minutes, and the increase peaked at 60 minutes. There 
was a significant reduction in right atrial pressure, pulmo-
nary capillary wedge pressure and systemic and pUlmonary 
vascular resistance. Mean arterial pressure decreased only 
slightly, and heart rate did not change. During initial and 
late evaluation, the hemodynamic effects of milrinone ap-
peared to last for 4 to 6 hours. 
The magnitude of changes in systemic hemodynamics 
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after acute and chronic milrinone therapy is illustrated in 
Figure 1. After chronic therapy, the magnitude of increase 
in cardiac index and stroke work index appeared to be less 
than that after initial therapy, but the difference did not 
reach statistical significance. The relative decrease in sys-
temic vascular resistance was similar after initial and chronic 
therapy as was the magnitude of reduction in pulmonary 
capillary wedge and right atrial pressures. 
Clinical Response 
The clinical responses to milrinone therapy in 37 patients 
with chronic congestive heart failure are illustrated in Figure 
2. New York Heart Association functional class is shown 
in relation to several time periods during therapy. "Pre-
drug" represents the time period immediately before oral 
milrinone therapy and at the time of initial hemodynamic 
evaluation. "Post-drug" represents the period of clinical 
follow-up after initiation of milrinone therapy, but before 
repeat hemodynamic study (range 2 to 45 days, mean 14). 
"Early" refers to the clinical status at the time of repeat 
hemodynamic testing (range 19 to 89 days, mean 37), and 
"late" refers to the time of latest clinical follow-up (range 
37 to 291 days, mean 165). Milrinone therapy was discon-
tinued in 12 of 37 patients before hospital discharge or 
follow-up hemodynamic study because of lack of clinical 
response, sudden death, serious side effects (ventricular 
tachycardia) or refusal to continue the study. 
Patients in functional class IV. Of 24 patients in func-
tional class IV at the time of initial hemodynamic evaluation, 
13 patients manifested immediate clinical improvement that 
correlated with hemodynamic improvement at the time of 
repeat study in 11 patients. The remaining 11 patients had 
no improvement symptomatically, and only 2 were able to 
be maintained on milrinone for repeat hemodynamic study. 
Of 13 patients whose condition improved initially, I patient 
died and 1 was withdrawn from the study because of wors-
ening congestive heart failure before the early follow-up 
evaluation. The condition of these patients deteriorated by 
late follow-up study, and 8 patients had sustained clinical 
benefit at the time of the last follow-up study. 
Patients in functional class III. Of 13 patients who 
were in functional class III at entry, 5 had early clinical 
improvement and 2 additional patients were in improved 
condition during the late follow-up evaluations. Five pa-
tients remained clinically unchanged initially, with one pa-
tient being withdrawn at early reevaluation because of lack 
of clinical response; two patients' condition deteriorated and 
two patients were without change symptomatically at last 
clinical follow-up study. The remaining patient died sud-
denly soon after the initial evaluation. 
Diuretic therapy. Twenty-three of the 28 patients dis-
charged from the hospital receiving maintenance milrinone 
therapy needed larger doses of diuretic drugs and anti-
Table 3. Acute and Chronic Hemodynamic Effects of Oral MUrinone in 25 Patients With Severe Congestive Heart Failure 
Heart rate 
(beats/min) 
MAP 
(mm Hg) 
RAP 
(mm Hg} 
PCW 
(mm Hg) 
SVR 
(dynes.s.cm -5) 
Baseline 
85 ± 18 
81 ± 12 
10 ± 7 
27 ± 8 
1,759 ± 493 
CI 1.9 ± 0.5 
(liters/min per m2) 
SWI 17.0 ± 80.8 
(g_mlm2) 
15 Min 
86 ± 17 
80 ± 12 
10 ± 7 
26 ± 8 
1,611 ± 482 
2.0 ± 0.6 
18.0 ± 8.2 
Heart rate 89 ± 23 86 ± 18 
(beats/min) 
MAP 80 ± 12 81 ± 13 
(mm Hg) 
RAP 12 ± 7 12 ± 7 
(mm Hg) 
PCW 28 ± 8 29 ± 8 
(mm Hg) 
SVR 1,625 ± 516 1,702 ± 513 
(dynes·s·cm- 5) 
CI 2.0 ± 0.6 2.0 ± 0.56 
(liters/min per m2 ) 
SWI 17.3 ± 10.4 17.5 ± 10.4 
(g-mlm2) 
30 Min 45 Min 60 Min 
A. Initial Study 
87 ± 17 88 ± 18 88 ± 16 
78 ± 14 75 ± 13t 73 ± iY* 
8 ± 6 7 ± 5t 6 ± 5* 
25 ± 8 21 ± 9t 20 ± 8* 
1,493 ± 471* 1,367 ± 455* 1,277 ± 405* 
2.2 ± 0.7t 2.4 ± 0.7* 2.5 ± 0.7* 
19.2 ± 7.9 20.4 ± 8.3 20.6 ± 8.5 
B. Second Study After Chronic Therapy 
90 ± 24 91 ± 26 92 ± 27 
79 ± II 77 ± lIt 77 ± lIt 
10 ± 7t 9 ± 8t 9 ± 8t 
27 ± 8 22 ± 9* 22 ± 9* 
1,520 ± 480 1,363 ± 453* 1,379 ± 395* 
2.2 ± 0.69 2.4 ± 0.75* 2.4 ± 0.79* 
18.5 ± 9.7 21.6 ± 11.4* 20.8 ± 9.9t 
*p < 0.001 versus baseline; tp > 0.01 versus baseline. Abbreviations as in Table I. 
90 Min 2 Hours 
88 ± 17 89 ± 17 
74 ± 12* 74 ± 10* 
6 ± 5* 6 ± 5* 
18 ± 8* 18 ± 8* 
1,290 ± 365* 1,235 ± 305* 
2.5 ± 0.71* 2.5 ± 0.71* 
21.8 ± lOt 22.5 ± 1O.6t 
91 ± 26 91 ± 25 
76 ± 12t 77 ± II 
8 ± 8* 9 ± 7* 
21 ± lO* 23 ± 9* 
1,358 ± 424* 1,432 ± 440t 
2.4 ± 0.75* 2.3 ± 0.75* 
21.6 ± 11.3* 20.2 ± lOt 
4 Hours 
89 ± 16 
75 ± II 
8 ± 7 
22 ± lOt 
1,364 ± 379* 
2.3 ± 0.65* 
20 ± 9.5 
90 ± 23 
78 ± 13 
9 ± 7 
24 ± 6t 
1,521 ± 454 
2.2 ± 0.58 
19 ± 9.5 
6 Hours 
89 ± 18 
76 ± 11 
9 ± 8 
24 ± 9 
1,460 ± 371* 
2.2 ± 0.54* 
18.3 ± 8.7 
88 ± 24 
78 ± 13 
10 ± 7 
26 ± 8 
1,547 ± 450 
2.1 ± 0.76 
18.0 ± 10.2 
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Figure 1. Acute and chronic hemodynamic effects of oral mil-
rinone in 25 patients. Hemodynamic changes are expressed as 
percent change (%1:» from baseline (control) and shown as a 
function of time after drug administration. Open circles and tri-
angles represent acute phase and closed circles and triangles 
represent chronic phase. Chronic hemodynamic effects were mea-
sured after an average of 37 days (range 19 to 89) of therapy. 
* = p < 0.01; ** = P < 0.001 compared with baseline. There 
was no significant difference between acute and chronic responses. 
CI = cardiac index (liters/min per m2); MAP = mean arterial 
pressure (mm Hg); MRAP = mean right atrial pressure (mm Hg); 
PCW = pulmonary capillary wedge pressure (mm Hg); SVR = 
systemic vascular resistance (dynes's'cm- 5); SWI = stroke work 
index (g-mlm2). 
aldosterone agents because of clinical evidence of increased 
systemic venous hypertension and fluid retention. 
Side effects (Table 4). No consistent change in hema-
tologic variables or hepatic enzymes occurred during main-
tenance milrinone therapy. One patient experienced mild 
diarrhea and one patient developed hyperthyroidism during 
therapy. Four patients had sustained ventricular tachycardia, 
resulting in discontinuation of milrinone therapy in one pa-
tient whose arrhythmia could not be suppressed with con-
ventional antiarrhythmic agents. 
Mortality. Four patients died in the hospital before dis-
charge despite initial hemodynamic improvement. Two ad-
ditional patients died within 1 month and another 10 patients 
died between 1 and 3 months of follow-up. The cumulative 
n 
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Figure 2. Clinical course of 37 patients treated with oral milrinone 
for chronic congestive heart failure. New York Heart Association 
functional class (II,I1I,IV) is shown in relation to baseline state 
(pre-drug), before repeat hemodynamic study (post-drug), at the 
time of repeat hemodynamic study (early) and at the time of latest 
clinical evaluation (late). See text for further explanation. 
survival rate for the entire group at 6 months was 34% (Fig. 
3). As expected, only 4 (17%) of 24 patients in functional 
class IV were alive during late follow-up; in contrast, 6 
Table 4. Side Effects of Oral Milrinone During Acute and 
Chronic Therapy 
Mild diarrhea 
No. of 
Patients 
Fluid retention requiring diuretic drugs 23 
Arrhythmias 
Sinus tachycardia 
Ventricular tachycardia 4 
(requiring discontinuation of milrinone in one patient) 
Hyperthyroidism 
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Figure 3. Cumulative survival of 37 patients with severe conges-
tive heart failure treated with long-term milrinone therapy. The 
overall survival of the entire group of 37 patients as the proportion 
surviving at each time interval up to 300 days of follow-up is 
shown on the Kaplan-Meier curve. See text for further explanation. 
(46%) of 13 patients in functional class III were alive at the 
time of late follow-up. The majority of patients died of 
uncontrolled heart failure, although nine patients died 
suddenly. 
Discussion 
Acute hemodynamic response. The present study con-
firms previous reports (5,6,10) that milrinone, a bipyridine 
derivative, produces beneficial hemodynamic effects in pa-
tients with severe congestive heart failure. At peak effect 
after oral milrinone for the entire group of 37 patients, there 
was an increase in cardiac index of 26% and a decrease in 
pulmonary capillary wedge pressure of 36%, with a signif-
icant but mild increase in heart rate and decrease in mean 
arterial pressure. As reported previously, a significant re-
duction in systemic venous pressure and systemic vascular 
resistance and an increase in stroke volume and stroke work 
also occurred after oral milrinone in our patients. 
Hemodynamic response after chronic therapy. The 
present study also suggests that the beneficial hemodynamic 
effects of oral milrinone may persist during maintenance 
therapy. The second hemodynamic study in 25 patients with 
severe congestive heart failure showed sustained increases 
in cardiac index and stroke work index, as well as decreases 
in systemic vascular resistance and pulmonary capillary wedge 
pressure after an average of 37 days of milrinone therapy. 
JACC Vol. 6, No.2 
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There were no statistically significant differences in the mag-
nitude of hemodynamic changes after acute and chronic oral 
milrinone therapy, although there was a trend toward di-
minished responses in cardiac index, stroke work index and 
systemic vascular resistance after chronic therapy (Fig. 1). 
The baseline hemodynamic values during the second study, 
which were determined 6 hours after the last oral dose, were 
not significantly different from the control values before 
initiation of milrinone therapy. For the group of 25 patients, 
control mean cardiac index was 1.9 ± 0.5 liters/min per 
m2 before initiation of therapy and 2.0 ± 0.6 liters/min per 
m2 after chronic therapy. These findings suggest that even 
after maintenance therapy, the effects of oral milrinone are 
unlikely to last longer than 6 hours. Sinoway et al. (5) 
reported hemodynamic deterioration in a much smaller num-
ber of patients after withdrawal of long-term milrinone ther-
apy. This is in contrast to our observations that left ven-
tricular function usually does not deteriorate after short-term 
maintenance therapy. In the study by Sinoway et al. (5), 
hemodynamic and clinical deterioration was observed an 
average of 26 hours after drug withdrawal. In our study, 
however, baseline hemodynamic studies were performed 
approximately 6 hours after the last oral dose. It needs to 
be emphasized that almost all patients received larger doses 
of diuretic drugs before the second hemodynamic study, and 
that the influence of altered diuretic drug dose on hemo-
dynamics remains unclear. 
Mechanism of hemodynamic improvement. This study 
was not designed to evaluate the mechanisms for the im-
provement in left ventricular function with milrinone in 
patients with chronic heart failure. The positive inotropic 
effect of milrinone has been demonstrated in animal ex-
periments (12). In this study, changes in contractile state 
were not assessed, and the potential contribution of the 
positive inotropic effects of milrinone remains unknown. In 
all of our patients, systemic vascular resistance decreased 
along with some reduction in arterial pressure. Thus, de-
creased left ventricular outflow resistance resulting from 
peripheral vasodilation must be at least one mechanism re-
sponsible for improved left ventricular function with mil-
rinone. It has been suggested that in some patients, left 
ventricular diastolic distensibility may increase with milri-
none (13) and other similar drugs (14). An increase in ap-
parent diastolic compliance is associated with improved left 
ventricular function. In our patients, although there was a 
marked decrease in pulmonary capillary wedge pressure and 
an increase in left ventricular stroke volume, indicating im-
proved left ventricular function, changes in left ventricular 
diastolic function were not evaluated. Therefore, the po-
tential contribution of such changes in improving systolic 
function in our patients remains uncertain. 
Clinical response. Symptomatic improvement occurred 
in approximately 50% (18 of 37) of our patients, although 
beneficial hemodynamic effects were documented in almost 
JACC Vol. 6, No.2 
August 1985 :453-9 
all patients during initial evaluation. The clinical improve-
ment was usually observed in the early follow-up period 
(post-drug). The majority of patients who improved clini-
cally could be discharged from the hospital and maintained 
the symptomatic improvement during the relatively short 
period of observation, although four patients' condition de-
teriorated despite milrinone therapy during the follow-up 
period. The majority of our patients had end-stage heart 
failure and were refractory to conventional and vasodilator 
drug therapy before institution of milrinone therapy. Almost 
all patients were symptomatic at rest or were unable to 
perform even limited physical activity. Therefore, objective 
evaluation in relation to changes in exercise tolerance was 
not possible in our study. However, marked relief of dys-
pnea and improved exercise tolerance were evident clini-
cally in a number of our patients. Thus, milrinone appears 
to have the potential to produce at least short-term symp-
tomatic improvement, even in moribund patients with end-
stage heart failure. 
The condition of some of our patients deteriorated rapidly 
after initial clinical and hemodynamic improvement, and 
almost all of these patients died. This is most likely a re-
flection of the severity of heart failure. This is also evident 
from the late high mortality rate in those patients who could 
be discharged from the hospital. In that group, the cumu-
lative mortality rate at 6 months was 66% (Fig. 3). As 
expected, late survival was somewhat better in patients in 
functional class III than in patients in functional class IV. 
A similar high mortality rate has been observed in patients 
with severe heart failure treated with other newer inotrope-
vasodilator agents (7). 
Adverse effects. Serious clinical problems were not en-
countered during milrinone therapy in our patients. Re-
cently, considerable side effects have been reported during 
maintenance amtinone therapy (15). Significant gastroin-
testinal disturbances (39%), neurologic complaints (17%), 
thrombocytopenia (10%) and hepatic dysfunction (7%) were 
reported in patients receiving oral amrinone therapy. Al-
though milrinone is an analog of amrinone, these side effects 
were not seen in our patients. The only serious adverse effect 
in our study was ventricular tachycardia in four patients 
during acute administration, requiring discontinuation of 
milrinone in one patient. The most common associated find-
ing was fluid retention requiring increased doses of diuretic 
drugs, presumably due in part to peripheral vasodilatory 
effects. The absence of frequent adverse effects of milrinone 
makes it preferable to amrinone for chronic use in congestive 
heart failure, and may allow the administration of larger 
doses with better hemodynamic and clinical response during 
long-term therapy. 
Implications. The present study clearly reveals that oral 
milrinone is effective in improving left ventricular perform-
ance during both acute and chronic administration in patients 
with severe congestive heart failure. Despite initial hemo-
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dynamic improvement, clinical improvement occurs in ap-
proximately half of these patients, but is sustained in the 
majority of those who improve. Adverse effects are minimal 
with chronic therapy, but overall mortality remains high 
even in patients who have a beneficial symptomatic re-
sponse. Clearly, further studies using randomized placebo-
controlled methods will be necessary to determine the ef-
ficacy of milrinone in the long-term management of patients 
with heart failure. 
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